- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| Do | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 28.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 27.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 26.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 23.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 22.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 21.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 17.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 16.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 14.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 10.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 07.10. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
| 23.09. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 2 | ASX | ||
| 19.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 18.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 18.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 17.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 05.09. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,045 | 0,00 % | Cannabis-Aktien: AKTIONÄR-Tipp Green Thumb dreht auf | Zum Wochenstart verzeichnet der Cannabis-Sektor eine Renencance. Zweistellige Kursgewinne sind dabei keine Seltenheit. Grund für den neuen Boom bei den Kiffer-Aktien: US-Präsident Donald Trump hat ein... ► Artikel lesen | |
| INDIVA | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.06.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.06.2025.ISIN NameCA45580J1012 INDIVA... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 375,70 | -0,32 % | ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales | ||
| CASSAVA SCIENCES | 2,737 | -1,33 % | Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update | Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 52,00 | 0,00 % | Nektar Therapeutics: Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting | SAN FRANCISCO, Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin... ► Artikel lesen | |
| ADASTRA | 0,132 | -3,65 % | Adastra Holdings Ltd.: Adastra Holdings Announces Completion of Sale of Subsidiaries | Langley, British Columbia--(Newsfile Corp. - October 15, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) (the "Company") announces that it has completed the sale of all of the issued and outstanding... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,586 | +1,67 % | SELLAS präsentiert Daten zu SLS009 bei rezidivierter Leukämie auf ASH-Tagung | ||
| CATALYST PHARMACEUTICALS | 18,345 | -1,45 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,870 | +2,37 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc. Provides Corporate Update | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Announces Change of Auditor | Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,184 | +2,22 % | ZELIRA THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | ||
| SOLIGENIX | 1,465 | -3,62 % | SOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:... ► Artikel lesen | |
| OPUS GENETICS | 1,926 | +3,88 % | Opus Genetics, Inc.: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) | Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.